Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2024, revenue amounted to SEK 26 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
Company Details
- Employees
- 2.14K
- Address
- Norra Stationsgatan 93a, Stockholm,stockholm County 11364,sweden
- Phone
- (468)697-2000
- in****@****obi.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- sobi.com
- Keywords
- orphan drugs, hereditary metabolic disorders, haemophilia, biopharmaceuticals, patient access, rare diseases, haematology, hematology, immunology, autoimmune.
- HQ
- Stockholm, Stockholm County
Sobi - Swedish Orphan Biovitrum Ab (Publ) Questions
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s helpline number is (468)697-2000
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s website is sobi.com
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s LinkedIn profile is https://se.linkedin.com/company/sobi
Sobi - Swedish Orphan Biovitrum Ab (Publ) has
2.14K employees.
View email and phone details for 2.14K
employees at Sobi - Swedish Orphan Biovitrum Ab (Publ).
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s industry is
Pharmaceutical Manufacturing
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s top competitors are
Roche,
Novartis,
Bristol Myers Squibb,
Idorsia Pharmaceuticals Ltd,
Takeda,
Sanofi,
Pfizer,
Biogen,
Sobi - North America,
Astrazeneca.
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s support email address is info@sobi.com
Sobi - Swedish Orphan Biovitrum Ab (Publ)'s categories are Pharmaceutical Manufacturing
